Loading…
Loading…
XFIN (ExcelFin Acquisition Corp.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
XFIN does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for XFIN and 80,000+ other tickers.
See exactly how XFIN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for XFIN and 80,000+ other tickers.
ExcelFin Acquisition Corp. currently possesses no substantial ongoing business activities. Its primary objective is to complete a strategic business combination, which may involve a merger, stock swap, asset acquisition, equity purchase, corporate restructuring, or a similar transaction, with one or more other enterprises. This company was established in 2021 and maintains its headquarters in San Francisco, California.
NEW YORK , Oct. 1, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China (which has recently expanded into the U.S. market following its receipt of US FDA 510(k) clearances), and ExcelFin Acquisition Corp. ("ExcelFin") (NASDAQ: XFIN), a publicly traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination"). The listed company resulting from the Business Combination is Baird Medical Investment Holdings Limited ("PubCo"), and its shares and warrants will commence trading on the Nasdaq under the ticker symbols "BDMD" and "BDMDW", respectively, on October 2, 2024.
FORT MILL, S.C. , Sept. 5, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China, and ExcelFin Acquisition Corp. ("ExcelFin") (NASDAQ: XFIN), a publicly traded special purpose acquisition company, today announced that Baird Medical Investment Holdings Limited's ("PubCo") registration statement on Form F-4 (the "Registration Statement") related to their previously announced proposed business combination (the "Business Combination") has been declared effective by the U.S. Securities and Exchange Commission (the "SEC").
Baird Medical agreed to subject 30% of its shares to be received in the transaction to an earnout at a $12.50 trading price Minimum cash condition of $15 million has been waived, cementing certainty and expediency to our transaction close Upon closing, Baird Medical is expected to trade on Nasdaq under the ticker symbol "BDMD" FORT MILL, S.C. , March 12, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China and the United States, and ExcelFin Acquisition Corp. ("ExcelFin") (NASDAQ: XFIN), a publicly traded special purpose acquisition company, today announced a strategic update to their previously announced business combination agreement.
NEW YORK , Oct. 17, 2023 /PRNewswire/ -- ExcelFin Acquisition Corp. ("we", "us", "our", or the "Company"), today announced that the Special Meeting originally scheduled for October 18, 2023 (the "Special Meeting") is being adjourned to October 20, 2023. At the Special Meeting, the Company's stockholders will be asked: to consider and vote upon a proposal to amend the Company's amended and restated certificate of incorporation (the "Charter") pursuant to a second amendment to the Charter (the "Extension Amendment") to extend the date by which the Company must effectuate an initial business combination from October 25, 2023 (the "Termination Date") to April 25, 2024, comprised of an initial three-month extension and three subsequent one-month extensions, for a total of six months after the Termination Date (assuming the Company's initial business combination has not occurred); and to consider and vote upon a proposal to adjourn the Special Meeting to a later date or dates, if necessary, to (i) permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Special Meeting, there are not sufficient votes to approve one or more proposals presented to stockholders for vote or (ii) if stockholders have elected to redeem an amount of shares in connection with the Extension Amendment such that the Company would not adhere to the continued listing requirements of The Nasdaq Global Market ("Nasdaq") (the "Adjournment Proposal").